AG真人官方

IDEAYA Biosciences, Inc. (IDYA) filed a Form 4 disclosing that Director Scott W. Morrison received an equity incentive on 24 June 2025. The award is a stock option for 20,000 common shares at an exercise price of $21.78 per share, expiring on 24 June 2035. According to the vesting schedule, 100 % of the option vests on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting, provided the director remains on the Board. After this grant, Morrison beneficially owns 20,000 derivative securities; no non-derivative shares were bought or sold. The filing reflects routine director compensation aimed at aligning governance incentives with shareholder interests and does not immediately alter the company鈥檚 share count or cash position.

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) filed an 8-K summarizing the outcomes of its 2025 Annual Meeting held on 24 June 2025.

• Equity Incentive Plan: Stockholders approved an amendment to the 2024 Equity Incentive Plan, adding 1,214,580 new shares of common stock available for grants. With 24,363,119 shares outstanding on the record date, the newly authorized pool represents approximately 5% potential dilution.
• Director Election: Dr. Daniel Baker was elected as a Class I director for a three-year term, receiving 18,913,133 votes in favor, 22,995 withheld, and 1,838,803 broker non-votes.
• Auditor Ratification: KPMG LLP was ratified as independent registered public accounting firm for fiscal 2025 with 20,772,359 votes for, 300 against, and 2,272 abstentions.
• Plan Approval Details: The equity plan amendment passed with 16,350,669 votes for, 2,583,159 against, 2,300 abstentions, and 1,838,803 broker non-votes.

No other material transactions, earnings data, or strategic shifts were reported.

Form 4 filing for T. Rowe Price Group, Inc. (TROW) dated 07/01/2025 discloses two insider share acquisitions by director Robert J. Stevens. Both transactions were executed under the company鈥檚 2017 Non-Employee Director Equity Plan and relate to dividend reinvestment and director fee awards rather than open-market buying.

• 06/27/2025: 267.1081 common shares acquired at a reported price of $96.10, reflecting automatic reinvestment of cash dividends. Post-transaction direct holdings rose to 20,478.9911 shares.
• 06/30/2025: 613 stock-unit shares issued in lieu of cash director fees at $96.50 per share (no cash outlay shown). These units vest immediately and are non-forfeitable. Direct holdings increased to 21,091.9911 shares.

No derivative securities were reported. Total incremental ownership equals 880.1081 shares (鈮�4.3 % increase to the director鈥檚 stake), representing roughly US $85鈥�$85.5 k based on the indicated share prices. The filing signals ongoing alignment between the director and shareholders but, given TROW鈥檚 multi-billion-dollar market capitalization, the dollar value is not material at the corporate level.

EnPro Industries, Inc. (NPO) 鈥� Form 4 insider filing

Director William Abbey reported a routine, non-open-market transaction dated 30 June 2025. He was credited with 130.5142 phantom stock units under the company鈥檚 Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock upon retirement (1-for-1 exchange) and does not have an expiration date.

The phantom units were valued at $191.55 per unit, implying a notional value of roughly $25,000. Following this accrual, Abbey鈥檚 total beneficial ownership of phantom stock stands at 1,197.7656 units. No common shares were bought or sold, and no derivative securities were disposed of. Ownership remains classified as direct.

The filing reflects standard deferred compensation activity rather than an active investment decision, therefore it is typically viewed as neutral from a market-impact perspective.

EnPro Industries, Inc. (NPO) 鈥� Form 4 insider filing

Director William Abbey reported a routine, non-open-market transaction dated 30 June 2025. He was credited with 130.5142 phantom stock units under the company鈥檚 Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock upon retirement (1-for-1 exchange) and does not have an expiration date.

The phantom units were valued at $191.55 per unit, implying a notional value of roughly $25,000. Following this accrual, Abbey鈥檚 total beneficial ownership of phantom stock stands at 1,197.7656 units. No common shares were bought or sold, and no derivative securities were disposed of. Ownership remains classified as direct.

The filing reflects standard deferred compensation activity rather than an active investment decision, therefore it is typically viewed as neutral from a market-impact perspective.

On June 24, 2025, First Bancorp (FBNC) Chief Operating Officer Christian A. Wilson reported the award of 3,028 shares of common stock under the company鈥檚 Long Term Incentive Plan at a deemed price of $42.12 per share. The shares will vest on June 24, 2028. After the grant, Wilson鈥檚 direct ownership rose to 8,463 shares. No derivative securities or open-market purchases were disclosed, and the transaction involves no immediate cash outflow. Overall, the filing documents a routine equity incentive that modestly tightens executive-shareholder alignment without signaling near-term changes to First Bancorp鈥檚 financial position.

T Rowe Price Group (TROW) Vice President Sebastien Page executed multiple transactions on June 18, 2025:

• Exercised three stock options totaling 17,059 shares: - 7,920 shares at $69.84 - 4,750 shares at $68.32 - 4,389 shares at $68.32
• Subsequently disposed of 14,300 shares at $92.14 per share
• Following these transactions, Page directly owns 64,375 shares
• The exercised options were from 2015 grants that vested 20% annually over 5 years

This pattern of exercising options and selling shares suggests a planned liquidation of vested equity compensation, executed near the expiration dates of the 2015 option grants which mature in September 2025.